Whether the combination of a once-daily inhaled corticosteroid with a once-daily longacting ( 2 ) agonist is more protective than a once-daily longacting ( 2 ) agonist alone against exacerbations of chronic obstructive pulmonary disease ( COPD ) is unknown .